Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function
拓扑替康
医学
内科学
药理学
化疗
作者
Seamus O’Reilly,Eric K. Rowinsky,William J. Slichenmyer,Ross C. Donehower,Arlene A. Forastiere,David S. Ettinger,Tian Ling Chen,S E Sartorius,Katherine Bowling,J. Smith,Abe Brubaker,Barbara Lubejko,Virna Ignacio,Louise B. Grochow
Background:Topotecan, a topoisomerase I inhibitor that has demonstrated anticancer activity toward leukemias and solid tumors in clinical trials, is eliminated via hepatic and renal routes. However, dosing guidelines for the administration of topotecan to patients with impaired hepatic function have not yet been established.